IMMUNOTHERAPY – Page 2 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2019-10-30

European Commission Approves Bavencio-Inlyta for First-line Treatment of Advanced Kidney Cancer

The European Commission (EC) has approved a combination regimen of Bavencio (avelumab) injections plus Inlyta (axitinib) tablets for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer. The combination can be used in patients regardless of their predicted prognosis and PD-L1 status. The EC’s decision followed a positive recommendation issued in September by the Committee for Medicinal

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-30

Implications of the Gut Microbiome for Cancer Immunotherapy

The immune system is very effective against invading pathogens such as viruses and bacteria, as well as cancer cells that arise through genetic mutation. The activity of the immune system must be kept in check, however, to maintain homeostasis and avoid the development of autoimmune conditions. The immunosuppressive mechanisms that accomplish this can be co-opted

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-29

Immunotherapy Advances: 2019

The year 2019 has offered up many advances in immunotherapy. These advances shed light on such important aspects as biomarkers, better targeted therapies, chemotherapy outcomes, and resistance. Summarized herein are several high-profile conference presentations that highlight key advances in the field. The year has not quite come to an end yet, but as predicted by

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-29

Scientists Find Molecular Key to Body Making Healthy T Cells

Researchers Seek New Therapies to Stop Immune Diseases In a finding that could help lead to new therapies for immune diseases like multiple sclerosis and IBD, scientists report in the Journal of Experimental Medicine identifying a gene and family of proteins critical to the formation of mature and fully functioning T cells in the immune system. T

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-24

Clues to improve cancer immunotherapy revealed

Helper T cells appear vital to more robust anti-tumor response Cancer immunotherapy drugs trigger the body’s immune system to attack tumors and have revolutionized the treatment of certain cancers, such as lymphoma, lung cancer and melanoma. Yet, while some patients respond well to the drugs, others don’t respond at all. Cancer immunologists want to change

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-17

Inactive receptor renders immunotherapies ineffective

Cancer: important reason for poor response to checkpoint inhibitors identified. The aim of immunotherapies is to enable the immune system once again to fight cancer on its own. Drugs known as checkpoint inhibitors are already in clinical use for this purpose. However, they are only effective in about one third of patients. Based on analysis

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-09

Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients[1],[2] Beovu demonstrated greater reductions in central subfield thickness (CST, a key indicator of fluid in the retina) as early as week 16 and at one year

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-08

Patient-tailored immunotherapies

Source Nature Biomedical Engineering

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-05

‘Express courier service’ for immune cells

Immunotherapy is a promising cancer treatment that uses genetically modified immune cells to fight cancer. It can be used as a primary treatment or in combination with other treatments such as radiation and chemotherapy to slow down or stop the growth of cancer cells and prevent them from spreading to other parts of the body.

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2019-10-04

Duvelisib Gains FDA Orphan Drug Designation for T-Cell Lymphomas

The FDA has granted duvelisib (Copiktra) with an orphan drug designation for the treatment of patients with T-cell lymphoma, according to a press release from Verastem Oncology, the company developing duvelisib.1 The PI3K-δ,γ inhibitor demonstrated efficacy in a phase I study and is currently being investigated in the phase II PRIMO trial (NCT03372057). “Receiving orphan

No Comments InIMMUNOTHERAPY

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category IMMUNOTHERAPY

European Commission Approves Bavencio-Inlyta for First-line Treatment of Advanced Kidney Cancer

Implications of the Gut Microbiome for Cancer Immunotherapy

Immunotherapy Advances: 2019

Scientists Find Molecular Key to Body Making Healthy T Cells

Clues to improve cancer immunotherapy revealed

Inactive receptor renders immunotherapies ineffective

Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept

Patient-tailored immunotherapies

‘Express courier service’ for immune cells

Duvelisib Gains FDA Orphan Drug Designation for T-Cell Lymphomas